Loading…
← CockpitCompetitor Analysis › SFZN.SW Siegfried Holding AGOpen in the cockpit ↗

Siegfried Holding AGSFZN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Pharmaceuticals: Major

Swiss contract manufacturer (CDMO) producing active pharmaceutical ingredients and finished drug products for pharma clients.

≈ A Swiss Lonza / CatalentMomentum laggard 6
Mkt cap
$3.51B
US dollars, full cap
Free float
83%
of shares outstanding
$/day
$9.09M
20-day average traded
Fwd P/E
16.8×
forward earnings
ROIC−WACC
+4.3 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
93 days
19 Feb 2027
Close · CHFCHF 67.75
1D+0.1%
1W-5.1%
1M-5.3%
3M-15.6%
6M-17.4%
YTD-9.2%
1Y-9.7%
ATR %2.7%
52w lowhigh33.3% off high

What Siegfried does

Swiss contract manufacturer (CDMO) producing active pharmaceutical ingredients and finished drug products for pharma clients.

Makes active ingredients and finished tablets or capsules to the customer's specification under supply agreements, so it sells manufacturing capacity and know-how, not drugs under its own name. Once a product is transferred, orders tend to continue for as long as the drug sells. Sites span Europe, the US and China.

In one line: A Swiss Lonza / Catalent.

Products and services

  • API manufacturing
  • Drug-product (finished dosage) manufacturing
  • Development services

Customers

  • Big pharma
  • Biotech companies (outsourced manufacturing)

Where it sits in the supply chain

  • Pharma services
  • CDMO
  • API & drug-product manufacturing

What could go right

  • Pharma CDMO outsourcing growth
  • Complex/high-potency molecule demand

What could go wrong

  • Customer concentration
  • Capacity-utilization cyclicality

Moat: narrow (regulatory licence, customer qualification, scale). FDA/EMA-approved manufacturing sites are costly and slow to requalify or replace.

Headquarters: Zofingen, Switzerland · Founded: 1873 · Employees: 3,891

Named competitors

Siegfried at a glance

Size Siegfried (SFZN.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $3.51B, the 71st largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 67.75 on 18 Nov 2026.

Performance Over six months the shares fell 17.4%, against +12.3% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue grew 3.6% over the last twelve months (peer median +10.3%); the operating margin is 15.7% (peer median 12.2%).

Valuation It trades at 16.8× forward earnings against a peer median of 20.1× (5th cheapest of 12).

Capital Return on invested capital runs 4.3 points above its cost of capital (5.0% WACC).

Next results Next results expected around 19 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 112SFZN.SW 83
Six months, rebased to 100: Siegfried against the median of its 20 peers (local-currency closes).

Siegfried financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 1.34BCHF 1.33BCHF 1.29BCHF 1.27BCHF 1.23B
Revenue growth—+3%+2%+3%—
Gross profitCHF 362MCHF 352MCHF 329MCHF 320MCHF 319M
EBITDACHF 313MCHF 307MCHF 277MCHF 249MCHF 310M
Net incomeCHF 171MCHF 169MCHF 160MCHF 113MCHF 156M
Free cash flow-CHF 18.2MCHF 9.97M-CHF 5.24MCHF 72.2MCHF 30.9M
Capital expenditureCHF 201MCHF 231MCHF 181MCHF 137MCHF 115M
Total debtn/aCHF 575MCHF 490MCHF 525MCHF 590M

Quarterly statements and history in the cockpit →

Siegfried competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%+40%WOCKPHARMAACUTAAS1877ARQT0022623320AMLX600521VRDN2096PPLPHARMAOGNSLS000739XENE1513ROVISFZN.SW6-month return →1-month return →
Up and to the right = strong over both horizons. Siegfried is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×50×100×150×ACUTAASARQT00226233202096PPLPHARMAOGN0007391513ROVISFZN.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Siegfried is the large dot.

Siegfried competitors and peer comparison

Head to head with its named competitors (SFZN.SW vs LONN.SW vs 603259.SS vs 002821.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Siegfried SFZN.SW$3.51B-17%+4%16%16.8×n/a
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
WuXi AppTec 603259.SS$64.2B+40%+32%43%17.0×7.2%
Asymchem Laboratories (Tianjin) 002821.SZ$7.27B+20%+18%17%37.4×n/a
Piramal Pharma PPLPHARMA.NS$3.40B+38%+9%3%150.8×n/a
Divi's Laboratories DIVISLAB.NS$31.3B+60%+22%34%73.5×47.1%

How Siegfried compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Siegfried against its 20 peers (data as of 18 Nov 2026)
MeasureSFZN.SWPeer medianRank in peer set
1-month return-5.3%+4.5%5th lowest of 21
6-month return-17.4%+12.3%3rd lowest of 20
Distance from 52-week high-33.3%-21.3%4th lowest of 21
Revenue growth (TTM)+3.6%+10.3%7th lowest of 18
Operating margin15.7%12.2%7th highest of 16
Forward P/E16.8×20.1×5th cheapest of 12
ROIC minus cost of capital+4.3 pp+3.7 pp8th highest of 16
EV / EBITDA12.1×23.9×4th cheapest of 9
Net debt / EBITDA2.6×1.2×4th most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%11.3×-7.0%+2.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%

Questions

Who are Siegfried's main competitors?
Named competitors: Lonza Group (LONN.SW), Catalent (private or unlisted), Recipharm (private or unlisted), Cambrex (private or unlisted), EUROAPI (private or unlisted), WuXi AppTec (603259.SS). The cockpit's measured peer set (industry) also includes Parabilis Medicines (PBLS), Wockhardt (WOCKPHARMA.NS), Acutaas Chemicals (ACUTAAS.NS), Shanghai Junshi Biosciences (1877.HK), Arcutis Biotherapeutics (ARQT), Jiangsu Nhwa Pharmaceutical (002262.SZ).
Is Siegfried expensive compared with its peers?
On forward p/e it trades at 16.8× against a peer median of 20.1×, 5th cheapest of 12 in its peer set.
How has Siegfried stock performed?
Over six months to 18 Nov 2026 the shares returned -17.4% against +12.3% for the median peer; over one year -9.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.